9 Reporting in Brachytherapy: Dose and Volume Specification

Reporting in Brachytherapy 209

When reporting at level 2/3, a series of CT and/or MRI sections are available as well as a 3-D dose distribution and DVHs can be derived. The dose distribution for the GTV and the PTV can then be derived. Dose volume analysis should be done for doses used in traditional reporting, e.g. 60, 75, 85 Gy. The dose distribution based on a point A prescription can also be analysed with regard to coverage of GTV and PTV. (e) The doses to the bladder and rectum ICRU reference points should be reported when reporting at level 1 (section 8.5.2-3). They can be evaluated from orthogonal radiographs, as defined in ICRU 38 (43). However, this evaluation takes time and is not always possible due to the local conditions. When reporting at level 2, a series of CT and/or MRI sections are available as well as a 3-D dose distribution. DVHs can then be derived. The maximum bladder and rectal dose in a certain volume (2 and 5 cm 3 ) should be reported as indicated in section 8.5.4. In addition, at level 2, the volume of the organ at risk receiving a dose close to or higher than the dose considered to be significant in relation to tolerance should also be reported (e.g. 60/70/80 Gy). (f) If in vivo measurements were performed, the method and the results should be reported.